Thromboserin Ltd is a UK-based biopharmaceutical company focused on developing and commercialising novel antiplatelet treatments. The company is run by an experienced team with deep roots in the pharmaceutical, academic and healthcare sectors.

Our lead product has completed Phase I and is currently being considered for a number of indications where its unique profile offers marked benefits over other newly approved and emerging compounds in this competitive market sector. We expect to achieve proof-of-concept for our first clinical indication in 2017.

Business highlights: 

Market Exclusivity in US and EU - granted and pending patents take IP cover to 2038 and 2025, respectively. 

High profit potential / low cost business model: low infrastructure, capital efficient business model; providing high value specialist products in response to unmet patient needs. 

For further information and details of investment opportunities go to www.thromboserin.com

Thromboserin Limited

Org chart

Teams

Offices